We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock
DCPH

Delisted

DCPH was delisted on the 10th of June, 2024.

Back to rankings

1 hedge funds and large institutions have $759K invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 174 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 177 → 1 (-176)

100% less capital invested

Capital invested by funds: $944M → $759K (-$943M)

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 174

Holders
1
Holders Change
-176
Holders Change %
-99.44%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
174
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$94.3M
2
AC
Armistice Capital
New York
-$92.8M
3
RG
Redmile Group
California
-$83.3M
4
DM
Deerfield Management
New York
-$80.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$71.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
DT
126
Diversified Trust
Tennessee
– -$201K -12,747 Closed
IA
127
Inspire Advisors
Idaho
– -$198K -12,577 Closed
Ohio Public Employees Retirement System (OPERS)
128
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$190K -12,050 Closed
Balyasny Asset Management
129
Balyasny Asset Management
Illinois
– -$185K -11,740 Closed
IB
130
Intrust Bank
Kansas
– -$182K -11,595 Closed
ACM
131
Aquatic Capital Management
Illinois
– -$171K -10,900 Closed
Lazard Asset Management
132
Lazard Asset Management
New York
– -$164K -10,445 Closed
EFM
133
E Fund Management
China
– -$162K -10,313 Closed
EC
134
EntryPoint Capital
New York
– -$154K -9,795 Closed
PAS
135
Point72 Asia (Singapore)
Singapore
– -$105K -6,654 Closed
AIP
136
Ameritas Investment Partners
Nebraska
– -$81.3K -5,166 Closed
Public Employees Retirement Association of Colorado
137
Public Employees Retirement Association of Colorado
Colorado
– -$71K -4,522 Closed
Royal Bank of Canada
138
Royal Bank of Canada
Ontario, Canada
– -$68K -4,304 Closed
CWM
139
Compass Wealth Management
Connecticut
– -$66.9K -4,250 Closed
MLICM
140
Metropolitan Life Insurance Company (MetLife)
New York
– -$47.8K -3,038 Closed
Canada Life
141
Canada Life
Manitoba, Canada
– -$37K -2,346 Closed
S
142
SignatureFD
Georgia
– -$34.6K -2,198 Closed
HT
143
Headlands Technologies
Illinois
– -$32.1K -2,038 Closed
QCG
144
Quadrant Capital Group
Ohio
– -$30.9K -1,965 Closed
AB
145
Amalgamated Bank
New York
– -$29K -1,817 Closed
AP
146
Atwood & Palmer
Missouri
– -$28.5K -1,811 Closed
AF
147
Allworth Financial
California
– -$25.2K -1,603 Closed
Osaic Holdings
148
Osaic Holdings
Arizona
– -$25.2K -1,603 Closed
SO
149
STRS Ohio
Ohio
– -$22K -1,400 Closed
TRCT
150
Tower Research Capital (TRC)
New York
– -$21.5K -1,364 Closed
3 4 5
6
7

DCPH Hedge Fund Activity: Q2 2024 in Review

1 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q2 2024, worth a combined $759K — down 100% from $944M a quarter earlier.

Sellers outnumbered buyers: 174 funds closed out of DCPH and 0 opened new positions — a net loss of 174 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $94.3M sold.

  • 1 institutional investor held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q2 2024, down from 177 in Q1 2024.
  • Funds reported $759K of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q2 2024 and 174 closed out, a net change of -174 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q2 2024 was BlackRock, an estimated $94.3M sold.

Based on aggregated 13F filings for Q2 2024.